Menu Search
Equities

ImmuneOnco Biopharmaceuticals Shanghai Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1541:HKG.HS

ImmuneOnco Biopharmaceuticals Shanghai Inc

Actions
  • Price (HKD)4.58
  • Today's Change0.150 / 3.39%
  • Shares traded860.80k
  • 1 Year change-17.03%
  • Beta--
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

ImmuneOnco Biopharmaceuticals Shanghai Inc is a China-based company mainly engaged in the development of tumor immunotherapy. The Company's main businesses include the development of biotechnology for the systemic utilization of innate and adaptive immunity, and the development of next-generation tumor immunotherapies, which primarily focus on the adaptive immune system. The Company's core product IMM01 is an innovative CD47-targeted molecule. The Company mainly operates its businesses in the domestic and overseas markets.

  • Revenue in HKD (TTM)126.96m
  • Net income in HKD-342.81m
  • Incorporated2015
  • Employees195.00
  • Location
    ImmuneOnco Biopharmaceuticals Shanghai IncSHANGHAI ChinaCHN
  • Phone+86 2 138016387
  • Websitehttp://immuneonco.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.